NICE provisionally rejects elacestrant for treating advanced breast cancer

Getty/yacobchuk

By Sarah Lowden

A new treatment for women with a type of advanced breast cancer has been provisionally rejected by the NHS spending watchdog.

In draft guidance the National Institute for Health and Care Excellence (NICE) said it does not recommend elacestrant for treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer with an activating ESR1 mutation.